Tumor Absorbed Dose-Response Relationship in Patients Treated With 177Lu-DOTATATE for Meningioma
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 11
- 试验地点
- 4
- 主要终点
- Diagnostic accuracy for progression free survival
研究概览
简要总结
The hypothesis for this study is that there is a dose-response relationship in patients treated with 177Lu-DOTATATE for meningiomas.
详细描述
Dosimetry is essential for Peptide Receptor Radionuclide Therapy (PRRT) of meningiomas, to predict efficacy and dose-effect relationships at the individual level, and to move towards personalized medicine. Due to the increasing therapeutic applications of Lutathera, the European Association of Nuclear Medicine (EANM) recently issued recommendations on the dosimetry of 177Lu-labeled somatostatin analogues. Nevertheless, despite these recommendations, the evaluation of meningioma tumor dosimetry in Peptide Receptor Radionuclide Therapy studies is not systematic, which has not enabled us to clearly determine the dose delivered to the meningioma lesion in these treatments and the possible dose-response relationship in this type of treatment.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patients treated for menigioma at nancy hospital
- •patients who performed 3 scintigraphics exams during there treatment
排除标准
- •patients deprived of liberty
- •patient who refused to collect data retrospectively
结局指标
主要结局
Diagnostic accuracy for progression free survival
时间窗: Day 1
Accuracy of tumor dosimetry to predict 6-month progression-free survival.
次要结局
- Diagnostic accuracy for overal survival(Day 1)
研究者
BOURSIER Caroline
Principal Investigator
Central Hospital, Nancy, France